Current medical news and unique business news for anyone who cares about the healthcare industry.
Federal Guidant suit. Guidant remains the gift that keeps on giving for Boston Scientific. The federal government is suing BSX for knowingly selling defective defibrillators.
Healthcare lobbying. Pharma cut its spending last year in federal lobbying, but physicians and hospitals fought on, according to a study of fourth-quarter disclosure reports. The difference in spending was largely defined by anyone who had unfinished business with the U.S. healthcare reform bill passed into law.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Merck getting serious on biosimilars.Via Xconomy:
“We need to have some humility about what biologics have done,” says Merv Turner, Merck’s chief strategy officer, in an interview at the JP Morgan Healthcare Conference in San Francisco earlier this month. “Biologics are going to be important in the future, and we have to get into biologics if we are going to be the world’s leading healthcare company, which is our ambition.”
Generation Alzheimer’s. One in eight Baby Boomers will develop Alzheimer’s disease — as many as 10 million.
Who’s an MD? Half of consumers have trouble discerning who is a doctor. Among those who consumers don’t think have MDs: orthopedic surgeons, family practitioners and dermatologists.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Global R & D on the rise. A Battelle study called research and development spending “stable.” Global spending on R & D will increase 3.6 percent.
